A new document advises physicians on using SBRT for high-risk scenarios involving tumor size and location and previous treatments for lung cancer in medically inoperable patients.
Vamsidhar Velcheti, MD, and his team are pursuing novel, targeted therapies for patients with a rare form of NSCLC.
The low-dose chest CT scan used for lung cancer screening frequently demonstrates incidental findings in the anatomic structures imaged from the neck to the upper abdomen. This study describes the frequency of incidental findings and their clinical and financial downstream effects.
Ground-breaking research shows combining radiology, especially stereotactic radiosurgery, and targeted drugs significantly increases survival in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Patients with choroidal metastases can see flashing lights, floating spots and have distortion of their vision. A careful history and physical examination can uncover signs and symptoms of hidden cancer.
Dr. Jordan Reynolds, anatomic and molecular pathologist, discusses a case that illustrates how to diagnose lung cancer on small specimens.
A centralized counseling and shared decision-making visit prior to lung cancer screening can help patients make value-based decisions about their care and ensure a lung cancer screening program is high quality and patient centered.
The cancer research “dream teams” organized and funded by Stand Up to Cancer unite scientists across disciplines and specialties to accelerate the development of innovative therapies. Cleveland Clinic Cancer Center oncologist Vamsi Velcheti, MD, joins the Lung Cancer Dream Team to work on immunotherapy-related biomarkers.
Cleveland Clinic medical oncologist James Stevenson, MD, discusses the coming sea-change in lung cancer care at the 2016 OncLive State of the Science Summit on Metastatic Non-Small Cell Lung Cancer.
Cleveland Clinic is collaborating with industry biomarker developers to improve lung cancer biomarkers on the market, as well as developing volatile organic compound biomarkers of the breath, urine and blood.